SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-188158
Filing Date
2023-07-17
Accepted
2023-07-17 16:44:53
Documents
12
Period of Report
2023-07-17
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K d506616d8k.htm   iXBRL 8-K 24752
  Complete submission text file 0001193125-23-188158.txt   146496

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA abos-20230717.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE abos-20230717_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abos-20230717_pre.xml EX-101.PRE 11259
6 EXTRACTED XBRL INSTANCE DOCUMENT d506616d8k_htm.xml XML 3341
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 231092046
SIC: 2836 Biological Products, (No Diagnostic Substances)